Business Context and Reporting Period
This Form 8-K filing by Progyny, Inc. (PGNY) reports corporate governance changes effective November 16, 2020. The Company, incorporated in Delaware and listed on The Nasdaq Global Select Market, is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the appointment of new directors and their compensation arrangements.
Material Changes
The Board of Directors appointed two new directors effective immediately:
- Malissia R. Clinton: Appointed as a director with a term expiring at the 2023 annual meeting. She was also appointed to the Nominating and Corporate Governance Committee.
- Roger C. Holstein: Appointed as a director with a term expiring at the 2021 annual meeting. He was also appointed to the Compensation Committee.
Compensation and Governance Details
Under the Company's non-employee director compensation policy, the new directors received the following:
- Cash Retainer: $40,000 annually.
- Initial Equity Grant: Options to purchase 44,000 shares of common stock, vesting 25% on the first anniversary and the remainder in equal quarterly installments over the next three years.
- Future Annual Grants: Eligibility for options to purchase 25,000 shares and 5,000 restricted stock units (RSUs) annually, granted on October 24, vesting on the first anniversary.
Both directors entered into the Company's standard indemnity agreement. No material family relationships or undisclosed transactions were reported.
Investor Verification Checklist
- Verify the impact of the new board composition on the Company's strategic direction, particularly regarding healthcare and technology expertise.
- Review the total dilution impact of the initial 44,000 share option grants per director and future annual grants.
- Confirm the specific vesting schedules and exercise prices of the granted options in subsequent filings.
- Monitor the Company's 2021 and 2023 annual meeting schedules for director term expirations.